

Printed from: Joint Formulary Committee. *British National Formulary*. 49 ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2005.

ZOPICLONE

Additional information: interactions ([Zopiclone](#)).

Indications: insomnia (short-term use—up to 4 weeks)

Cautions: hepatic impairment (avoid if severe; [Appendix 2](#)) and renal impairment ([Appendix 3](#)); elderly; history of drug abuse, psychiatric illness; avoid prolonged use (and abrupt withdrawal thereafter); **interactions:** Appendix 1 (anxiolytics and hypnotics)

DRIVING. Drowsiness may persist the next day and affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced

Contra-indications: myasthenia gravis, respiratory failure, severe sleep apnoea syndrome, severe hepatic impairment; pregnancy and breast-feeding ([Appendix 5](#))

Side-effects: bitter or metallic taste; gastro-intestinal disturbances including nausea and vomiting, dry mouth, aggression; irritability, confusion, depressed mood; drowsiness, dizziness, lightheadedness, and incoordination, headache; dependence; hypersensitivity reactions reported (including urticaria and rashes); hallucinations, nightmares, amnesia reported

Dose: 7.5 mg at bedtime; ELDERLY initially 3.75 mg at bedtime increased if necessary; CHILD not recommended

Sub-sections

[Zopiclone](#)

[Zimovane®](#)

Copyright © British Medical Association and Royal Pharmaceutical Society of Great Britain 2005. All rights reserved.
[Accessibility](#) | [Terms of Use](#)